CN101945653B - 用于治疗神经变性疾病的组合物和方法 - Google Patents

用于治疗神经变性疾病的组合物和方法 Download PDF

Info

Publication number
CN101945653B
CN101945653B CN2008801266113A CN200880126611A CN101945653B CN 101945653 B CN101945653 B CN 101945653B CN 2008801266113 A CN2008801266113 A CN 2008801266113A CN 200880126611 A CN200880126611 A CN 200880126611A CN 101945653 B CN101945653 B CN 101945653B
Authority
CN
China
Prior art keywords
cla
ala
compositions
disease
presbyacusis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801266113A
Other languages
English (en)
Chinese (zh)
Other versions
CN101945653A (zh
Inventor
梁谷慎一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Bio Co Ltd USA
Original Assignee
Marine Bio Co Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Bio Co Ltd USA filed Critical Marine Bio Co Ltd USA
Publication of CN101945653A publication Critical patent/CN101945653A/zh
Application granted granted Critical
Publication of CN101945653B publication Critical patent/CN101945653B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801266113A 2008-01-02 2008-12-31 用于治疗神经变性疾病的组合物和方法 Expired - Fee Related CN101945653B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1859408P 2008-01-02 2008-01-02
US61/018,594 2008-01-02
PCT/US2008/088660 WO2009088939A2 (en) 2008-01-02 2008-12-31 Compositions and methods for treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
CN101945653A CN101945653A (zh) 2011-01-12
CN101945653B true CN101945653B (zh) 2013-01-16

Family

ID=40798719

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801266113A Expired - Fee Related CN101945653B (zh) 2008-01-02 2008-12-31 用于治疗神经变性疾病的组合物和方法

Country Status (6)

Country Link
US (2) US8168675B2 (enExample)
EP (1) EP2237777A4 (enExample)
JP (1) JP5575662B2 (enExample)
KR (1) KR101417201B1 (enExample)
CN (1) CN101945653B (enExample)
WO (1) WO2009088939A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3174544B1 (en) 2014-07-31 2020-12-09 Universita' Degli Studi Di Cagliari Ester of a phospholipid with conjugated linoleic acid for the treatment of psychiatric disorders with neuroinflammatory and neurodegenerative basis
EP3903776A4 (en) * 2018-12-25 2022-10-05 Demencare Laboratory Inc. COMPOSITION FOR IMPROVING COGNITIVE FUNCTIONS
KR102557719B1 (ko) * 2019-04-26 2023-07-20 가톨릭대학교 산학협력단 항산화제가 담지된 나노입자를 유효성분으로 포함하는 귀 질환 치료용 약학 조성물
CN113892460A (zh) * 2021-09-29 2022-01-07 滨州医学院 Nod-b6重组近交系小鼠模型的构建方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177558A1 (en) * 2000-04-21 2002-11-28 Meyerhoff James L. Method of treating, preventing or inhibiting central nervous system injuries and diseases
US20030055099A1 (en) * 2001-09-19 2003-03-20 Martynyuk Anatoly E. Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
US20050107338A1 (en) * 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2543587B2 (ja) * 1989-01-05 1996-10-16 帝人株式会社 語音聴力改善剤
US5670539A (en) * 1993-07-21 1997-09-23 New York State Office Of Mental Health Treatment of movement disorders using large neutral amino acids
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
IT1290907B1 (it) * 1997-01-31 1998-12-14 Idi Farmaceutici Spa Composizione per prodotto dietetico efficace nel combattere lo stress ossidativo e il decadimento cellulare.
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
GB0003310D0 (en) * 2000-02-15 2000-04-05 Univ Sheffield Bone formation
DE10027968A1 (de) * 2000-06-08 2001-12-13 Asta Medica Ag Mittel zur Therapie von Demenzen
CN1105097C (zh) * 2000-09-14 2003-04-09 国家海洋局第一海洋研究所 微囊化共轭亚油酸
US20030045541A1 (en) * 2001-07-23 2003-03-06 Christopher Bruckner GABA-Receptor modulators with NMDA-Antagonistic activity
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
AR048335A1 (es) * 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
US7901675B2 (en) * 2004-10-13 2011-03-08 U.S. Department Of Veterans Affairs Method of using coenzyme Q10 to treat Huntington's disease
JP2006151909A (ja) * 2004-11-30 2006-06-15 Rohto Pharmaceut Co Ltd 内服用組成物
CN1850065A (zh) * 2005-04-23 2006-10-25 中山市尤利卡天然药物有限公司 口服共轭亚油酸及其衍生物用于增肌健体与皮肤美容的用途
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
JP2006212021A (ja) * 2005-08-05 2006-08-17 Ajinomoto Co Inc 食品組成物
US20080234197A1 (en) * 2007-03-19 2008-09-25 Undurti N Das Method(s) of stabilizing and potentiating the actions and administration of brain-derived neurotrophic factor (BDNF)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177558A1 (en) * 2000-04-21 2002-11-28 Meyerhoff James L. Method of treating, preventing or inhibiting central nervous system injuries and diseases
US20030055099A1 (en) * 2001-09-19 2003-03-20 Martynyuk Anatoly E. Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
US20050107338A1 (en) * 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《Effect of water-soluble coenzyme Q10 on noise-induced hearing loss in guinea pigs》;HIROSE Y ET AL;《ACTA OTO-LARYNGOLOGICA.》;SUPPLEMENTUM,SCANDINAVIAN UNIVERSITY PRESS.OSLO,NO,;19890101;第128卷(第10期);摘要 *

Also Published As

Publication number Publication date
WO2009088939A3 (en) 2009-09-11
WO2009088939A2 (en) 2009-07-16
US20090169533A1 (en) 2009-07-02
US20120189600A1 (en) 2012-07-26
KR101417201B1 (ko) 2014-07-08
CN101945653A (zh) 2011-01-12
EP2237777A2 (en) 2010-10-13
EP2237777A4 (en) 2011-03-30
US8168675B2 (en) 2012-05-01
KR20100098553A (ko) 2010-09-07
JP2011509257A (ja) 2011-03-24
JP5575662B2 (ja) 2014-08-20

Similar Documents

Publication Publication Date Title
Bockbrader et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin
EP2224930B1 (en) Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
CA2292497C (en) Dietary compositions for enhancing metabolism and alleviating oxidative stress
RU2605330C2 (ru) Способы и композиции, подходящие для укрепления здоровья кожи
EP2464350B1 (en) Compositions and methods for enhancing cognitive and related functions in animals
HUE035426T2 (hu) Probiotikus és prebiotikus komponenseket és ásványi sókat tartalmazó készítmények laktoferrinnel
JPH06504259A (ja) 高コレステロール血症および細胞過増殖性障害の予防および処置用処方および方法
CN101820754A (zh) 用于增强认知功能的组合物与方法
KR20150018897A (ko) 나이와 관련된 기억 손상의 치료를 위한 케톤 생성 조성물의 용도
JP2016513966A (ja) サーチュイン活性化剤によるペットの処置
CN101405054A (zh) 用于保护脑功能的组合物和方法
Alam et al. Efficacy of Spirulina (Tahlab) in patients of type 2 diabetes mellitus (Ziabetus Shakri): A randomized controlled trial
NZ536889A (en) Use of pullulan as a slowly digested carbohydrate
CN101945653B (zh) 用于治疗神经变性疾病的组合物和方法
JP5537151B2 (ja) 精神安定剤および機能性食品
EP2070523B1 (en) Composition comprising Magnolol and Honokiol in synergistic amount
US20070054965A1 (en) AMPK activating agent
EP1656130B1 (en) Omega-3 fatty acids for the treatment of canine ostheoarthritis
JP2021078397A (ja) 脂質減少促進剤
US20110162981A1 (en) Methods and compositions for preventing, reducting or treating damage caused by ischemia and schemia-like conditions
KR101319075B1 (ko) 신경퇴행성 질환의 치료를 위한 조성물 및 방법
US20210260022A1 (en) Synergy for increasing energy expenditure and insulin sensitivity
Hoffer Negative and positive side effects of vitamin B3
TW201919646A (zh) 提升葡萄糖胺類之生物學利用率的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130116

CF01 Termination of patent right due to non-payment of annual fee